To determine which of the two pathways was engaged in EMT-related effects, the CRC cells were treated with JAK inhibitor JAKi1 (10 uM) or PI3K inhibitor LY294002 (0.1 uM) 1 h before IL-13 treatment (Figure 3B). The gene discussed is IL13; the disease is colorectal carcinoma.